Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.060 AlteredExpression disease BEFREE Decreased expression of the p16 protein was identified in 25 of 77 LMSs (32%). 14595762 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.060 Biomarker disease BEFREE Using tissue microarrays and cases from Tulane Medical Center and Medical College of Wisconsin, expression of smoothelin, DOG1, caldesmon, and p16 was evaluated by immunohistochemistry in 87 cases of LMS. 29189258 2017
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.060 Biomarker disease BEFREE Compared with leiomyoma (LM), the figures for the strength of association were as follows: LM variants (RR = 1.53, 95%CI = 1.03-2.27, P = 0.036, random effect); leiomyosarcoma (LMS) (RR = 3.20, 95%CI = 1.68-6.12, P < 0.001, random effect); and smooth muscle tumors of uncertain malignant potential (STUMP) (RR = 2.90, 95%CI = 1.17-7.21, P = 0.022, random effect). p16INK4a expression was significantly higher in LMS than in LM variants (RR = 3.74, 95%CI = 1.96-7.13, P < 0.001, random effect) or STUMP (RR = 1.67, 95%CI = 1.26-2.23, P < 0.001, fixed effect). 28340268 2017
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.060 AlteredExpression disease BEFREE Although p14 inactivation or overexpression of the human murine double minute homolog (HDM2) were frequent in LMS and UPS and could substitute for TP53 mutation or deletion, such alterations were rare in angiosarcomas. 22648906 2012
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.060 AlteredExpression disease BEFREE A number of genes were found to be differentially expressed in these sample sets, and six genes including cyclin-dependent kinase inhibitor 2A, diaphanous (Drosophila homolog) 3, doublecortin, calpain 6, interleukin-17B, and proteolipid 1 were found to be overexpressed in LMS compared with normal myometrium and 18 other tissues. 12942572 2003
Entrez Id: 1041
Gene Symbol: CDSN
CDSN
0.010 Biomarker disease BEFREE Mutations in thePTDSS1gene coding one of the phosphatidylserine (PS) synthase enzymes, PSS1, were described as causative in LMS patients. 27044099 2016
Entrez Id: 1073
Gene Symbol: CFL2
CFL2
0.010 AlteredExpression disease BEFREE Immunohistochemistry (IHC) was performed on LMS tissue microarrays (n=377) for five markers with high levels of messenger RNA in the muscle-enriched cluster (ACTG2, CASQ2, SLMAP, CFL2 and MYLK) and showed significantly correlated expression of the five proteins (all pairwise P<0.005). 19901961 2010
Entrez Id: 10970
Gene Symbol: CKAP4
CKAP4
0.030 GeneticVariation disease BEFREE Moreover, we show that transcription of Dlx3 is abrogated by mutations in the sterile alpha-motif (SAM) domain of p63 that are associated with ankyloblepharon-ectodermal dysplasia-clefting (AEC) dysplasias, but not by mutations found in ectrodactylyectodermal dysplasia-cleft lip/palate (EEC), Limb-mammary syndrome (LMS) and split hand-foot malformation (SHFM) dysplasias. 17164413 2007
Entrez Id: 10970
Gene Symbol: CKAP4
CKAP4
0.030 GeneticVariation disease BEFREE The third hallmark of the EEC syndrome is orofacial clefting, in particular lip and palate. p63 mutations also cause the other five inherited syndromes: symptoms are overlapping, but each of these diseases has its own characteristic phenotypic features: for instance AEC syndrome (ankyloblepharon-ectodermal defects-cleft lip/palate) has as distinctive feature ankyloblepharon, while mammary glands and nipples hypoplasia are frequent findings in LMS syndrome and in ADULT syndrome (acro-dermato-ungual-lacrimal-tooth syndrome). 23407076 2013
Entrez Id: 10970
Gene Symbol: CKAP4
CKAP4
0.030 GeneticVariation disease BEFREE We performed p63 mutation analysis in a sample of 43 individuals and families affected with EEC syndrome, in 35 individuals affected with SHFM, and in three families with the EEC-like condition limb-mammary syndrome (LMS), which is characterized by ectrodactyly, cleft palate, and mammary-gland abnormalities. 11462173 2001
Entrez Id: 1312
Gene Symbol: COMT
COMT
0.010 AlteredExpression disease BEFREE Major vault protein (MVP) and catechol O-methyltransferase had 3.05 and 13.94 times higher expression in LMS relative to LM by sequential window acquisition of all theoretical fragment ion spectra mass spectrometry, respectively. 29307622 2018
Entrez Id: 1435
Gene Symbol: CSF1
CSF1
0.010 Biomarker disease BEFREE Together, these findings suggest an important role for CSF1 and the resulting TAM infiltration in the pathological neovascularization of LMS tumors and provide a rationale for CSF1-targeted therapies in LMS. 21854753 2011
Entrez Id: 1440
Gene Symbol: CSF3
CSF3
0.010 Biomarker disease BEFREE For this reason, we evaluated the combination of 900 mg/m(2) gemcitabine plus 70 mg/m(2) docetaxel regimen without prophylactic G-CSF support in advanced or recurrent LMS and UES in Japanese patients. 24149774 2014
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.010 AlteredExpression disease BEFREE Nuclear beta-catenin expression was observed in 23% of the LMS (p=0.051), 61% of ESS (p=0.628) and in the sarcoma component of 68% of the AS. 19622417 2009
Entrez Id: 1611
Gene Symbol: DAP
DAP
0.010 GeneticVariation disease BEFREE In conclusion, although DAP kinase alteration was relatively rare, DAP kinase alteration and/or p53 mutation may associate with tumor progression in soft-tissue LMSs. 15492995 2004
Entrez Id: 1674
Gene Symbol: DES
DES
0.020 AlteredExpression disease BEFREE Expression of desmin and/or H-caldesmon was detected in 8/10 LMS PDX models. 28625393 2017
Entrez Id: 1674
Gene Symbol: DES
DES
0.020 Biomarker disease BEFREE The primary tumor was clearly positive for á-smooth muscle type actin and desmin in moderately differentiated areas and indicated a loss of myogenic differentiation in other regions and therefore was classified as a poorly differentiated LMS. 9664117 1998
Entrez Id: 1747
Gene Symbol: DLX3
DLX3
0.010 GeneticVariation disease BEFREE Moreover, we show that transcription of Dlx3 is abrogated by mutations in the sterile alpha-motif (SAM) domain of p63 that are associated with ankyloblepharon-ectodermal dysplasia-clefting (AEC) dysplasias, but not by mutations found in ectrodactylyectodermal dysplasia-cleft lip/palate (EEC), Limb-mammary syndrome (LMS) and split hand-foot malformation (SHFM) dysplasias. 17164413 2007
Entrez Id: 1756
Gene Symbol: DMD
DMD
0.010 Biomarker disease BEFREE Dystrophin inhibits myogenic sarcoma cell migration, invasion, anchorage independence and invadopodia formation, and dystrophin inactivation was found in 96%, 100% and 62% of metastatic GIST, embryonal RMS and LMS samples, respectively. 24793134 2014
Entrez Id: 1913
Gene Symbol: EEC1
EEC1
0.010 Biomarker disease BEFREE We performed p63 mutation analysis in a sample of 43 individuals and families affected with EEC syndrome, in 35 individuals affected with SHFM, and in three families with the EEC-like condition limb-mammary syndrome (LMS), which is characterized by ectrodactyly, cleft palate, and mammary-gland abnormalities. 11462173 2001
Entrez Id: 2006
Gene Symbol: ELN
ELN
0.010 Biomarker disease BEFREE In the present study, we modulated versican expression using siRNAs in the human leiomyosarcoma (LMS) smooth muscle cell line SK-LMS-1, and observed the formation of elastin and elastic fibers in vitro and also in vivo in a nude mouse tumor model. 26723257 2016
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.040 Biomarker disease BEFREE The presence of estrogen receptor staining may be helpful in identifying uterine versus nonuterine LMS. 10574596 1999
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.040 Biomarker disease BEFREE It highlights the difficulty in classifying some gastrointestinal SMNs as either LMs or LMSs and the importance of ER status in SMNs. 30431607 2018
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.040 AlteredExpression disease BEFREE Compared to these tumors, the expression of both ER and PR was markedly reduced in LMS. 9891238 1999
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.040 Biomarker disease BEFREE We selected 17 biomarkers highly relevant to LMS in 4 tumorigenic pathways including steroid hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]), cell cycle/tumor suppressor genes, AKT pathway markers, and associated oncogenes. 29258902 2018